Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease

OBJECTIVES: This paper presents an Australian model that formed part of the health technology assessment for public investment in siltuximab for the rare condition of idiopathic Multicentric Castleman Disease (iMCD) in Australia. METHODS: Two literature reviews were conducted to identify the appropr...

Descripción completa

Detalles Bibliográficos
Autores principales: Shupo, Francis, Abrams, Keith R., Ademi, Zanfina, Wayi-Wayi, Grace, Zibelnik, Natasa, Kirchmann, Matt, Rutherford, Carolyn, Makarounas-Kirchmann, Kelly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471559/
https://www.ncbi.nlm.nih.gov/pubmed/37306929
http://dx.doi.org/10.1007/s41669-023-00426-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471559/
https://www.ncbi.nlm.nih.gov/pubmed/37306929
http://dx.doi.org/10.1007/s41669-023-00426-x

Ejemplares similares